Fiche publication
Date publication
décembre 2014
Journal
Expert review of hematology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr PAGLIUCA Simona
Tous les auteurs :
Marotta S, Pagliuca S, Risitano AM
Lien Pubmed
Résumé
Aplastic anemia (AA) is a bone marrow failure syndrome characterized by pancytopenia and an empty bone marrow. Standard treatments for AA include immunosuppressive therapy and bone marrow transplantation (BMT). BMT is the preferred option for young AA patients with a sibling donor, whereas in older patients or in those to be grafted from an unrelated donor BMT is exploited as second-line treatment. Current results of BMT for AA demonstrate cure rates up to 80 and 70% in BMT from HLA-matched siblings and unrelated donor, respectively, with age and stem cell source largely affecting the outcome. BMT is also a potential treatment option for paroxysmal nocturnal hemoglobinuria, a rare hematological disorder characterized by complement-mediated intravascular hemolytic anemia, thrombophilia and bone marrow failure.
Mots clés
aplastic anemia, bone marrow failure, bone marrow transplantation, immunosuppressive treatment, paroxysmal nocturnal hemoglobinuria
Référence
Expert Rev Hematol. 2014 12;7(6):775-89
